Apelin in epiretinal fibrovascular membranes of patients with retinopathy of prematurity and the changes after intravitreal bevacizumab

Retina

Volumn 33, Issue 3, 2013, Pages 613-620

  Zhang, Yan ^a,b   Jiang, Yan Rong ^a,b   Lu, Qiang ^a,b   Yin, Hong ^a,b   Tao, Yong ^a,b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

apelin; bevacizumab; epiretinal fibrovascular membranes; neovascularization; retinopathy of prematurity

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; APELIN; BEVACIZUMAB; CD31 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; VASCULOTROPIN;

ANTIGEN EXPRESSION; ARTICLE; ASTROCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIRETINAL MEMBRANE; FLUORESCENCE ANALYSIS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEWBORN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETINA MACULA HOLE; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VITRECTOMY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD31; EPIRETINAL MEMBRANE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GESTATIONAL AGE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFANT; INFANT, NEWBORN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRAVITREAL INJECTIONS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, G-PROTEIN-COUPLED; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY;

EID: 84874947696     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31826d3a76     Document Type: Article

References (38)

1. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 2007;10:133-140
2. Gilbert C. Retinopathy of prematurity: A global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008;84:77-82
3. Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol 2003;8:469-474
4. Werdich XQ, McCollum GW, Rajaratnam VS, Penn JS. Variable oxygen and retinal VEGF levels: Correlation with incidence and severity of pathology in a rat model of oxygeninduced retinopathy. Exp Eye Res 2004;79:623-630
5. Kwinta P, Bik-Multanowski M, Mitkowska Z, et al. The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:1467-1475
6. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995;15:4738-4747
7. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995;1:182-193
8. Nazari H, Modarres M, Parvaresh MM, Ghasemi Falavarjani K. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol. 2010;248:1713-1718
9. Law JC, Recchia FM, Morrison DG, et al. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS 2010;14:6-10
10. Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: A pilot study. Br J Ophthalmol 2008;92:1450-1455
11. Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez- Rojas ML, et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008;28:S19-S25
12. Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008;28:S13-S18
13. Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:1061-1063
14. Hou J, Tao Y, Jiang YR, et al. Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: A matched study. Chin Med J (Engl) 2009; 122:2695-2699
15. Tao Y, Hou J, Jiang YR, et al. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye 2010;24:810-815
16. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009;54:372-400
17. Simo R, Hernandez C. Intravitreous anti-VEGF for diabetic retinopathy: Hopes and fears for a new therapeutic strategy. Diabetologia 2008;51:1574-1580
18. Jiang Y, Liang X, Li X, et al. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol 2009;87:736-740
19. Wirostko B, Wong TY, Simo R. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res 2008; 27:608-621
20. Patel JI, Tombran-Tink J, Hykin PG, et al. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. Exp Eye Res 2006;82:798-806
21. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251:471-476
22. Japp AG, Newby DE. The apelin-APJ system in heart failure: Pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 2008;75:1882-1892
23. Kasai A, Shintani N, Oda M, et al. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 2004;325:395-400
24. Cox CM, D'Agostino SL, Miller MK, et al. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol 2006;296:177-189
25. Kalin RE, Kretz MP, Meyer AM, et al. Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. Dev Biol 2007;305:599-614
26. Sorli SC, Le Gonidec S, Knibiehler B, Audigier Y. Apelin is a potent activator of tumour neoangiogenesis. Oncogene 2007; 26:7692-7699
27. Tao Y, Lu Q, Jiang YR, et al. Apelin in plasma and vitreous and in fibrovascular retinal membranes of patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2010;51:4237-4242
28. Zhao T, Lu Q, Tao Y, et al. Effects of apelin and vascular endothelial growth factor on central retinal vein occlusion in monkey eyes intravitreally injected with bevacizumab: A preliminary study. Mol Vis 2011;17:1044-1055. 29. 30
29. Masri B, van den Berghe L, Sorli C, et al. Apelin signalisation and vascular physiopathology [in French]. J Soc Biol 2009; 203:171-179
30. Saint-Geniez M, Masri B, Malecaze F, et al. Expression of the murine msr/apj receptor and its ligand apelin is upregulated during formation of the retinal vessels. Mech Dev 2002;110:183-186
31. Saint-Geniez M, Argence CB, Knibiehler B, Audigier Y. The msr/apj gene encoding the apelin receptor is an early and specific marker of the venous phenotype in the retinal vasculature. Gene Expr Patterns 2003;3:467-472
32. Masri B, Morin N, Cornu M, et al. Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. FASEB J 2004;18:1909-1911
33. Ronkainen VP, Ronkainen JJ, Hanninen SL, et al. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J 2007;21:1821-1830
34. Glassford AJ, Yue P, Sheikh AY, et al. HIF-1 regulates hypoxia- And insulin-induced expression of apelin in adipocytes. Am J Physiol Endocrinol Metab 2007;293:E1590-E1596
35. Eyries M, Siegfried G, Ciumas M, et al. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res 2008;103:432-440
36. Semenza GL, Agani F, Iyer N, et al. Regulation of cardiovascular development and physiology by hypoxia-inducible factor 1. Ann N Y Acad Sci 1999;874:262-268
37. Kidoya H, Ueno M, Yamada Y, et al. Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J 2008;27:522-534
38. Qian J, Lu Q, Tao Y, Jiang YR. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Retina 2011;31:161-168